GlassScriptPhysician profile
Steven A Edds
NPI 1205362274
$1,296.01
in general payments reported to CMS, 2019-2025
21 companies · $766 in 2025
The $766 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $153 · 2021: $85.06 · 2022: $15.11 · 2023: $58.63 · 2024: $218 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,043.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $369.03 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.30 | 2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.21 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Gilead Sciences, INC. | $89.66 | 2025 | |
| Janssen Biotech, INC. | $86.18 | 2024-2025 | Tremfya |
| Pfizer INC. | $83.48 | 2020-2025 | |
| Genzyme Corporation | $82.06 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $72.96 | 2020-2021 | |
| Medtronic, INC. | $66.79 | 2024 | Nexpowder |
| Allergan, INC. | $45.74 | 2020 | |
| Novo Nordisk INC | $35.42 | 2020-2025 | Wegovy |
| Organon LLC | $19.83 | 2025 | Renflexis, Hadlima |
| Ardelyx, INC. | $18.67 | 2025 | Ibsrela |
| Pulmonx Corporation | $17.87 | 2024 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Braintree Laboratories, INC. | $16.93 | 2025 | Suflave |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $16.86 | 2024 | Zymfentra |
| Mylan Specialty L.P. | $16.02 | 2020 | |
| Phathom Pharmaceuticals, INC. | $15.23 | 2025 | Voquezna |
| Lilly USA, LLC | $14.34 | 2025 | Omvoh |
| Merck Sharp & Dohme LLC | $14.23 | 2021 | |
| Boston Scientific Corporation | $14.20 | 2023 | Wallflex Duodenal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Edds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.